Mystic Asset Management Inc. Buys 4,550 Shares of Zoetis Inc. (NYSE:ZTS)

Mystic Asset Management Inc. grew its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 79.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,251 shares of the company's stock after purchasing an additional 4,550 shares during the period. Mystic Asset Management Inc.'s holdings in Zoetis were worth $1,688,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. HUB Investment Partners LLC increased its position in shares of Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after acquiring an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC increased its position in shares of Zoetis by 18.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after acquiring an additional 64 shares in the last quarter. Legacy Financial Advisors Inc. increased its position in shares of Zoetis by 5.8% during the fourth quarter. Legacy Financial Advisors Inc. now owns 1,282 shares of the company's stock worth $209,000 after acquiring an additional 70 shares in the last quarter. Quotient Wealth Partners LLC increased its position in shares of Zoetis by 2.3% during the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock worth $521,000 after acquiring an additional 72 shares in the last quarter. Finally, Broadway Wealth Solutions Inc. increased its position in shares of Zoetis by 4.4% during the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock worth $287,000 after acquiring an additional 73 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ZTS shares. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $180.00 to $155.00 in a research report on Thursday. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler upped their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. UBS Group reduced their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Finally, Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Zoetis has an average rating of "Moderate Buy" and an average target price of $204.63.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.18% of the company's stock.

Zoetis Stock Performance

ZTS traded down $1.42 during midday trading on Friday, reaching $148.61. The company had a trading volume of 4,723,160 shares, compared to its average volume of 2,619,032. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. The stock has a market cap of $66.16 billion, a PE ratio of 26.68, a P/E/G ratio of 2.51 and a beta of 0.91. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The business has a 50-day moving average price of $161.00 and a two-hundred day moving average price of $161.54.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.38 earnings per share. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.35%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's payout ratio is currently 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.